ethyl 2-cyano-2-(2,2,6,6-tetramethyl-4-phenyloxan-4-yl)acetate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 2-cyano-2-(2,2,6,6-tetramethyl-4-phenyloxan-4-yl)acetate
• 英文别名: ethyl 2-cyano-2-(2,2,6,6-tetramethyl-4-phenyltetrahydro-2H-pyran-4-yl)acetate；Ethyl 2-cyano-2-(2,2,6,6-tetramethyl-4-phenyloxan-4-yl)acetate
• 化学式: C₂₀H₂₇NO₃
• 分子量: 329.439
• InChiKey: VOIGKXABPDNUNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  59.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-cyano-2-(2,2,6,6-tetramethyl-4-phenyloxan-4-yl)acetate 在 lithium aluminium tetrahydride 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 potassium hydroxide 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 乙醚 、 乙二醇 、 甲苯 为溶剂， 反应 3.5h， 生成 3-chloro-N-(3-chlorophenyl)-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline
  参考文献：
  名称：

  Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)

  摘要：

  A series of tetrahydropyranyl (THP) derivatives has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents. Structural modification of the submicromolar hit compound 3 led to the potent 3-methoxy substituted analogue 27. Further SAR development around the THP ring resulted in an additional 10-fold increase in potency, exemplified by analogue 75 with an IC50 of 1.3 nM. Active and potent compounds demonstrated a dose-dependent increase in Ras cytosolic protein. Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI(50)) values ranging from 0.3 to >100 mu M. However, none of the cellular effects observed using ICMT inhibitors were as pronounced as those resulting from a farnesyltransferase inhibitor.

  DOI：

  10.1021/jm200249a
• 作为产物：
  描述：

  2,6-二甲基-2,5-庚二烯-4-酮 在 盐酸 、 ammonium acetate 、 水 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 240.0h， 生成 ethyl 2-cyano-2-(2,2,6,6-tetramethyl-4-phenyloxan-4-yl)acetate
  参考文献：
  名称：

  [EN] TETRAHYDROPYRAN-4-YLETHYLAMINO- OR TETRAHYDROPYRANYL-4-ETHYLOXY-PYRIMIDINES OR -PYRIDAZINES AS ISOPRENYLCYSTEINCARBOXYMETHYL TRANSFERASE INHIBITORS
  [FR] PYRIMIDINES OU PYRIDAZINES TÉTRAHYDROPYRAN-4-YLÉTHYLAMINO- OU TÉTRAHYDROPYRANYL-4-ÉTHYLOXY UTILES COMME INHIBITEURS DE L'ISOPRÉNYL-CYSTÉINE-CARBOXY-MÉTHYL-TRANSFÉRASE

  摘要：

  化合物的结构式（I）：其中：R1选自：（i）苯基，可选择一个氟原子取代；（ii）噻吩基；（iii）呋喃基；（iv）C1-4烷基；和（v）氢；R2选自：（II），R3选自：（III），X选自NH和O；R4选自苯基，5-成员杂环基或6-成员杂环基，均可选择一个或多个取代基，所述取代基选自：甲基，甲氧基，三氟甲基，三氟甲氧基，氰基，氟原子，-OC2H4OMe和吡唑基。

  公开号：

  WO2014041349A1

文献信息

• 이소프레닐시스테인카복실메틸트랜스퍼라제 저해제를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
  申请人：Research ＆ Business Foundation SUNGKYUNKWAN UNIVERSITY 성균관대학교산학협력단(220050013604) BRN ▼101-82-12009

  公开号：KR20170088140A

  公开（公告）日：2017-08-01

  본 발명은 이소프레닐시스테인카복실메틸트랜스퍼라제 저해제(ICMT_Ph), 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 ICMT_Ph는, 프로스타글란딘(prostaglandin E2: PGE) 및 종양사멸인자-알파(Tumor Necrosis Factor-α: TNF-α)의 생성을 억제한다는 것이 확인되어, 염증성 질환의 예방 또는 치료에 유용한 의약품 및 건강기능식품으로 사용될 수 있다.

  本发明涉及一种抑制异戊酰丝氨酸羧甲基转移酶(ICMT_Ph)的抑制剂，以及含有其作为有效成分的用于预防或治疗炎症性疾病的组合物。根据本发明，ICMT_Ph已被确认可以抑制前列腺素E2（PGE）和肿瘤坏死因子-α（TNF-α）的产生，因此可以作为对预防或治疗炎症性疾病有用的药物和保健食品使用。
• [EN] TETRAHYDROPYRAN-4-YLETHYLAMINO- OR TETRAHYDROPYRANYL-4-ETHYLOXY-PYRIMIDINES OR -PYRIDAZINES AS ISOPRENYLCYSTEINCARBOXYMETHYL TRANSFERASE INHIBITORS<br/>[FR] PYRIMIDINES OU PYRIDAZINES TÉTRAHYDROPYRAN-4-YLÉTHYLAMINO- OU TÉTRAHYDROPYRANYL-4-ÉTHYLOXY UTILES COMME INHIBITEURS DE L'ISOPRÉNYL-CYSTÉINE-CARBOXY-MÉTHYL-TRANSFÉRASE
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2014041349A1

  公开（公告）日：2014-03-20

  A compound of formula (I): wherein: R1 is selected from: (i) phenyl, optionally substituted by one fluoro group; (ii) thienyl; (iii) furanyl; (iv) C1-4 alkyl; and (v) H; R2 is selected from: (II), R3 is selected from: (III), X is selected from NH and O; R4 is selected from phenyl, a 5-membered heteroaryl or a 6-membered heteroaryl, all of which are optionally substituted by one or more substituents selected from the group consisting of: methyl, methoxy, trifluoromethyl, trifluoromethoxy, cyano, fluoro, -OC2H4OMe, and pyrazolyl.

  化合物的结构式（I）：其中：R1选自：（i）苯基，可选择一个氟原子取代；（ii）噻吩基；（iii）呋喃基；（iv）C1-4烷基；和（v）氢；R2选自：（II），R3选自：（III），X选自NH和O；R4选自苯基，5-成员杂环基或6-成员杂环基，均可选择一个或多个取代基，所述取代基选自：甲基，甲氧基，三氟甲基，三氟甲氧基，氰基，氟原子，-OC2H4OMe和吡唑基。
• Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)
  作者：Weston R. Judd、Paul M. Slattum、Khanh C. Hoang、Leena Bhoite、Liisa Valppu、Glen Alberts、Brita Brown、Bruce Roth、Kirill Ostanin、Liwen Huang、Daniel Wettstein、Burt Richards、J. Adam Willardsen

  DOI：10.1021/jm200249a

  日期：2011.7.28

  A series of tetrahydropyranyl (THP) derivatives has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents. Structural modification of the submicromolar hit compound 3 led to the potent 3-methoxy substituted analogue 27. Further SAR development around the THP ring resulted in an additional 10-fold increase in potency, exemplified by analogue 75 with an IC50 of 1.3 nM. Active and potent compounds demonstrated a dose-dependent increase in Ras cytosolic protein. Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI(50)) values ranging from 0.3 to >100 mu M. However, none of the cellular effects observed using ICMT inhibitors were as pronounced as those resulting from a farnesyltransferase inhibitor.